Abstract
Several groups are assessing the use of cationic lipids for respiratory gene therapy. To date no human data are available regarding the safety of intra-pulmonary cationic lipid delivery. In preparation for a trial of pulmonary delivery of the CFTR gene, we have assessed the safety of nebulised lipid GL-67/DOPE/DMPE-PEG5000 (GL-67A), the cationic lipid formulation to be used in this study. Fifteen healthy volunteers were given incremental doses of GL-67A via a Pari LC Jet nebuliser; three volunteers in each of five dosing cohorts with a week interval between cohorts. Markers of safety included clinical assessment, measurement of lung function, chest CT scan, serological testing and analysis of induced sputum. Measurements were taken before administration and at intervals up to 21 days thereafter. No adverse clinical events were seen or any statistically significant changes in spirometry or gas transfer. There were no clinically significant changes in any of the blood parameters and no CT changes were seen. Comparisons of the cellular subpopulations (neutrophils, eosinophils, lymphocytes and macrophages) in induced sputum showed no significant alterations following administration of the GL-67A. This study suggests that a single application of aerosol formulation of GL-67A does not result in clinically detectable changes when given by nebulisation into the lungs of normal volunteers and provides an indication of a lipid dose tolerated in man.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chadwick, S., Kingston, H., Stern, M. et al. Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther 4, 937–942 (1997). https://doi.org/10.1038/sj.gt.3300481
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300481
Keywords
This article is cited by
-
Construction of Spherical Liposome on Solid Transducers for Electrochemical DNA Sensing and Transfection
Applied Biochemistry and Biotechnology (2014)
-
Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung
Gene Therapy (2011)
-
Electroporation as a method for high-level nonviral gene transfer to the lung
Gene Therapy (2003)
-
Visualization of the transgene distribution according to the administration route allows prediction of the transfection efficacy and validation of the results obtained
Gene Therapy (2002)
-
Biodistribution and transgene expression with nonviral cationic vector/DNA complexes in the lungs
Gene Therapy (2000)